{{Rsnum
|rsid=700518
|Gene=CYP19A1
|Chromosome=15
|position=51236915
|Orientation=minus
|ReferenceAllele=A
|GMAF=0.3682
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CYP19A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.6 | 46.9 | 34.5
| HCB | 32.8 | 45.3 | 21.9
| JPT | 38.9 | 44.2 | 16.8
| YRI | 76.2 | 21.8 | 2.0
| ASW | 73.7 | 22.8 | 3.5
| CHB | 32.8 | 45.3 | 21.9
| CHD | 31.2 | 46.8 | 22.0
| GIH | 44.6 | 42.6 | 12.9
| LWK | 77.3 | 20.9 | 1.8
| MEX | 41.4 | 50.0 | 8.6
| MKK | 50.6 | 40.4 | 9.0
| TSI | 36.3 | 39.2 | 24.5
| HapMapRevision=28
}}[[rs700518]] is a SNP potentially linked in a gender-specific manner to [[hypertension]]
{{PMID|18274619|OA=1
}}

{{ neighbor
| rsid = 17703883
| distance = 985
}}

{{omim
|desc=CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1; CYP19A1
|id=107910
|rsnum=700518
}}

{{PMID Auto
|PMID=19921206
|Title=Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample
|OA=1
}}

{{PMID Auto
|PMID=22104650
|Title=A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women
|OA=1
}}

{{PMID Auto
|PMID=21442439
|Title=Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
}}

{{PMID Auto
|PMID=16733710
|Title=Association analyses of CYP19 gene polymorphisms with height variation in a large sample of Caucasian nuclear families.
|OA=1
}}

{{PMID Auto
|PMID=16782804
|Title=Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.
|OA=1
}}

{{PMID Auto
|PMID=17002564
|Title=Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction.
|OA=1
}}

{{PMID Auto
|PMID=17118999
|Title=Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
}}

{{PMID Auto
|PMID=17903296
|Title=Genome-wide association with bone mass and geometry in the Framingham Heart Study.
|OA=1
}}

{{PMID Auto
|PMID=18445666
|Title=Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels.
|OA=1
}}

{{PMID Auto
|PMID=19168589
|Title=Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China.
|OA=1
}}

{{PMID Auto
|PMID=19194457
|Title=Association between arterial stiffness and variations in oestrogen-related genes.
|OA=1
}}

{{PMID Auto
|PMID=22638611
|Title=Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy.
}}

{{PMID Auto
|PMID=23643682
|Title=Genetic Polymorphism at Val(80) (rs700518) of the CYP19A1 Gene is Associated with Aromatase Inhibitor Associated Bone Loss in Women with ER (+) Breast Cancer
}}

{{PMID Auto
|PMID=23700878
|Title=Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer
}}

{{PMID Auto
|PMID=22887836
|Title=Estrogen and the male hippocampus: genetic variation in the aromatase gene predicting serum estrogen is associated with hippocampal gray matter volume in men.
}}

{{PMID Auto
|PMID=23408108
|Title=Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
|OA=1
}}

{{PMID Auto
|PMID=24968701
|Title=CYP19 gene variant confers susceptibility to endometriosis-associated infertility in Chinese women
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}